EUCTR2009-011161-87-FR进行中（未招募）不适用
Treatment of anemia in myelodysplastic syndromes low risk with epoetin beta with Analysis of impact on quality of life and functional capacity - GFM-EPO-Qo
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Written informed consent;
- •Must be 18 years of age or older at the time of screening ;
- •Myelodysplastic Syndrome of the following subtypes : RA, RAS, RCMD, RCMD-RS, RAEB 1, with IPSS score low or intermediate 1 (IPSS score < 1 ) and with anemia defined by Hb < 10 g/dl (with RBC transfusion requirement or not);
- •For women of childbearing potential, need for effective contraception throughout the study period.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Intensive Chemotherapy within 3 months before inclusion;
- •Myelodysplastic Syndrome with IPSS score >1 ;
- •Treatment with rHu-Epo or rHu-GCSF within 2 months before inclusion
- •Other causes of anemia (eg. , Iron deficiency, vitamin B12 or folic acid, hypothyroidism before correction)
- •Uncontrolled arterial hypertension
- •Life expectancy less than 6 months
- •Pregnant or breast feeding female subjects
- •Patients with creatinine clearance less than 30ml/min
研究者
相似试验
Unknown
2 期
Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic AcidAnemia in Myelodysplastic SyndromesNCT00437450Groupe Francophone des Myelodysplasies99
进行中（未招募）
不适用
Cohort Study Assessing the Treatment Strategy for High-Risk Myelodysplastic Syndromes in Patients Under 70Myelodysplastic SyndromesNCT05367583University Hospital, Bordeaux107
招募中
1 期
Advancing treatment therapies in MyelodysplasiaMyelodysplasiaCancer - Leukaemia - Acute leukaemiaACTRN12622000410752Australasian Leukaemia and Lymphoma Group (ALLG)1,000
进行中（未招募）
1 期
Treatment of an imminent recurrence of the disease in patients with a Myelodysplastic syndrome or acute myeloid leukemia with azacitidine (Vidaza®)EUCTR2010-022388-37-DETechnische Universität Dresden93
招募中
2 期
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require TransfusionsMyelodysplastic SyndromesAnemiaNCT05384691University of Leipzig213